A study by the Evernorth Research Institute looking at national prescription drug use trends found GLP-1 use between 2023-2024 rose 84.6% in Gen Alpha (ages 14 and younger). The age group was ...

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...

A follow-up study is in the works to better track why patients stop taking their GLP-1 drugs, researchers said. More information Harvard Medical School has more on GLP-1 drugs .

Use of GLP-1 Drugs to Treat Overweight or Obesity Increased 587 Percent from 2019 to 2024, According to New FAIR Health Study Provided by PR Newswire May 27, 2025, 12:11:00 PM ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

When researchers analyzed weight loss results from patients who took GLP-1 drugs and those who'd undergone bariatric surgery, ...

Of the 102,166 GLP-1s analyzed, 94% had some form of commercial insurance, yet cost-saving options were still widely overlooked.

But in recent years, the emergence of newer GLP-1 drugs like semaglutide (the active ingredient in Ozempic and Wegovy) has dramatically changed the field of obesity medicine.

The rising use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss is changing how Americans eat, with implications already visible in the food and beverage industry. A new study from ...

A new study finds that the diabetes drug liraglutide significantly reduced monthly migraine days in patients with obesity and ...

In a matched group of more than 170,000 adults, those treated with GLP-1 agonists had a lower risk of developing an obesity-related cancer over a median follow-up of about 4 years when compared ...